David R. Spigel
Impact in
- Oncology top 0.05%
- Lung Cancer Research Studies
- Cancer Immunotherapy and Biomarkers
- Colorectal Cancer Treatments and Studies
- Pulmonary and Respiratory Medicine top 0.05%
- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
Papers in
- Oncology 406
- Lung Cancer Research Studies 134
- Cancer Immunotherapy and Biomarkers 121
- Colorectal Cancer Treatments and Studies 76
- Cancer Treatment and Pharmacology 41
-
- Lung Cancer Treatments and Mutations 214
- Lung Cancer Diagnosis and Treatment 57
- Co-authors
- John D. Hainsworth (172 shared papers)F. Anthony Greco (135 shared papers)Howard A. Burris (126 shared papers)Scott Antonia (33 shared papers)David Waterhouse (44 shared papers)Scott Gettinger (32 shared papers)Julie R. Brahmer (31 shared papers)Lecia V. Sequist (17 shared papers)
- Journals
- Journal of Clinical Oncology (290 papers)Annals of Oncology (67 papers)Journal of Thoracic Oncology (56 papers)Cancer Research (20 papers)Clinical Lung Cancer (15 papers)
- Partner nations
- United StatesUnited KingdomSpain
In The Last Decade
David R. Spigel
594 papers receiving 19.9k citations
David R. Spigel's Hit Papers
Peers
Comparison fields: 5 of 127
- Oncology 11.9k
- Pulmonary and Respiratory Medicine 7.7k
- Cancer Research 2.2k
- Hepatology 806
- Pathology and Forensic Medicine 1.7k
Countries citing papers authored by David R. Spigel
This map shows the geographic impact of David R. Spigel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David R. Spigel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David R. Spigel more than expected).
Fields of papers citing papers by David R. Spigel
This network shows the impact of papers produced by David R. Spigel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David R. Spigel. The network helps show where David R. Spigel may publish in the future.
Co-authors
The 25 scholars most cited alongside David R. Spigel, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 612 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | First-Line Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer Harboring SomaticEGFRMutations Hit paper breakdown → | 2008 | 663 |
| 2 | A Randomized Phase IIIB Trial of Chemotherapy, Bevacizumab, and Panitumumab Compared With Chemotherapy and Bevacizumab Alone for Metastatic Colorectal Cancer Hit paper breakdown → | 2008 | 645 |
| 3 | Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non–Small-Cell Lung Cancer: Results From the CA209-003 Study Hit paper breakdown → | 2018 | 545 |
| 4 | Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non–Small Cell Lung Cancer Treated With Nivolumab Hit paper breakdown → | 2019 | 424 |
| 5 | Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial Hit paper breakdown → | 2017 | 417 |
| 6 | Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer Hit paper breakdown → | 2016 | 401 |
| 7 | Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study Hit paper breakdown → | 2019 | 387 |
| 8 | Randomized Phase II Trial of Onartuzumab in Combination With Erlotinib in Patients With Advanced Non–Small-Cell Lung Cancer Hit paper breakdown → | 2013 | 371 |
| 9 | Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study Hit paper breakdown → | 2018 | 363 |
| 10 | Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study Hit paper breakdown → | 2018 | 342 |
| 11 | Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC—Update from PACIFIC Hit paper breakdown → | 2019 | 310 |
| 12 | Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non–Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial Hit paper breakdown → | 2015 | 289 |
| 13 | 2013 | 284 | |
| 14 | Multicenter Phase II Study of Whole-Body and Intracranial Activity With Ceritinib in Patients With ALK -Rearranged Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib: Results From ASCEND-2 Hit paper breakdown → | 2016 | 276 |
| 15 | 2007 | 271 | |
| 16 | 2007 | 265 | |
| 17 | Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study Hit paper breakdown → | 2021 | 263 |
| 18 | 2004 | 254 | |
| 19 | Adjuvant Systemic Therapy and Adjuvant Radiation Therapy for Stage I to IIIA Completely Resected Non–Small-Cell Lung Cancers: American Society of Clinical Oncology/Cancer Care Ontario Clinical Practice Guideline Update Hit paper breakdown → | 2017 | 245 |
| 20 | 2012 | 239 |
About David R. Spigel
David R. Spigel is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Cancer Research, Molecular Biology and Epidemiology, having authored 612 papers that have together received 20.3k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (214 papers), Lung Cancer Research Studies (134 papers), Cancer Immunotherapy and Biomarkers (121 papers), Cancer Genomics and Diagnostics (82 papers), Colorectal Cancer Treatments and Studies (76 papers), Lung Cancer Diagnosis and Treatment (57 papers), Cancer Treatment and Pharmacology (41 papers) and Cancer therapeutics and mechanisms (39 papers). The work is most often cited by research in Oncology (11.9k citations), Pulmonary and Respiratory Medicine (7.7k citations), Cancer Research (2.2k citations), Hepatology (806 citations) and Pathology and Forensic Medicine (1.7k citations). David R. Spigel has collaborated with scholars based in United States, United Kingdom and Spain. Frequent co-authors include John D. Hainsworth, F. Anthony Greco, Howard A. Burris, Scott Antonia, David Waterhouse, Scott Gettinger, Julie R. Brahmer, Lecia V. Sequist, Mark A. Socinski and Tony Mok. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Journal of Thoracic Oncology, Cancer Research and Clinical Lung Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.